MiR-15/107 microRNAs are important genetic regulators in Alzheimer disease
MiR-15/107 microRNAs are important genetic regulators in Alzheimer disease
批准号:
8550180
负责人:
PETER T. NELSON
金额:
$37.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2014-06-30
关键词:
AddressAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease riskAstrocytesBase of the BrainBiochemistryBrainCDK5 geneCancer cell lineCultured CellsCyclic AMP-Dependent Protein KinasesDataFundingFutureGene ExpressionGene Expression RegulationGenesGeneticGlucoseGoalsGrantHumanInflammatoryKnowledgeLaboratoriesLeadLentivirus VectorLinkMessenger RNAMetabolicMetabolic DiseasesMetabolic PathwayMethodsMicroRNAsMicrogliaModificationMolecular ProfilingMusNeuronsOrganismOverlapping GenesPathogenesisPathway interactionsPatientsProductionProteinsRNARNA SequencesRattusReagentResearch Project GrantsResearch ProposalsRoleSignal PathwaySmall Interfering RNASmall RNAStimulusSubfamily lentivirinaeTherapeuticTherapeutic AgentsTranscriptUp-RegulationViral VectorWorkbasebeta-site APP cleaving enzyme 1brain cellcofilindesigngene therapyinnovationneurochemistrynovelresearch studytau phosphorylationtau-protein kinasetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The miR-15/107 miRNA group are paralogous microRNAs (miRNAs), with overlapping gene regulatory impact, that are downregulated in Alzheimer's disease (AD) brains. Our underlying hypothesis is that miR- 15/107 gene augmentation (up-regulation) will help to reduce brain cellular expression of BACE1 and tau kinases (PKA and CDK5-regulating proteins). We have strong preliminary evidence in support of this hypothesis. The overall goal of the present research proposal is to obtain information necessary to develop future miRNA-based brain therapies and to increase our knowledge about miRNAs' role in AD. Therapeutic strategies must involve either stimulating endogenous miRNA production, or, alternatively, a "gene therapy" approach with exogenously introduced RNA or viral vectors. The key challenges, before developing brain therapies related to miR-15/107 genes, are 1> to understand upstream stimuli that alter miR-15/107 expression in human brains, and 2> define downstream genes regulated by these miRNAs, including an assessment of the potential for manipulating the "off-target effects" of miR-15/107-related miRNAs. We thus propose novel experiments in human brain and in primary rat brain-derived cultured cells. Specific Aims for this research project: Specific Aim #1: Define the specific AD-relevant signaling pathways that modulate miR-15/107 gene expression. Aim 1A: Perform hypothesis-based studies in cultured rat primary brain cells anchored in our preliminary results finding that glucose levels and discrete neuroinflammatory stimuli specifically alter miR-15/107 gene expression which may suggest strategies for miRNA-based therapies. Aim 1B: Perform comprehensive miR-15/107 expression profiling in human brain to understand how parameters linked with AD risk correlate with altered miR-15/107 gene expression because miRNA neurochemical studies need to be anchored in human brain data. Specific Aim #2: Define the exact "downstream" mRNA targets regulated by miR-15/107 genes in primary cultured rat brain cells. Preliminary data indicate that miR-15/107 genes may be a key mechanistic link between metabolic changes and increased tau phosphorylation in human brains. Using methods that were developed and optimized in our laboratory, we will perform comprehensive analyses of miR-15/107 miRNA targets in primary cultured rat brain cells. Specific Aim #3: Manipulate and minimize "off-target" effects of miRNAs using RNA sequence modifications in primary cultured brain cells. Cultured neurons will be transduced with lentivirus vectors harboring altered sequences related to miR-15/107 genes. We have already generated miRNA expressing lentivirus and transduced primary cultured neurons to help optimize the potential impact of miRNA-based therapies in the brain. The overall goal is to produce reagents with optimal "on-target" and minimal "off-target" impact, in order to maximize the potential value of small RNA- based therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core D: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10662352
-
项目类别:
-
资助金额:$28.07万
-
财政年份:2021
-
负责人:PETER T. NELSON
-
依托单位:
Core D: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10459469
-
项目类别:
-
资助金额:$28.01万
-
财政年份:2021
-
负责人:PETER T. NELSON
-
依托单位:
Core D: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10261965
-
项目类别:
-
资助金额:$28.57万
-
财政年份:2021
-
负责人:PETER T. NELSON
-
依托单位:
Novel misfolded proteins in ADRD: proteomics, genetics, and clinical-pathological correlations
-
批准号:9905466
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2019
-
负责人:PETER T. NELSON
-
依托单位:
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic
-
批准号:9912063
-
项目类别:
-
资助金额:$43.41万
-
财政年份:2017
-
负责人:PETER T. NELSON
-
依托单位:
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic
-
批准号:9402752
-
项目类别:
-
资助金额:$45.86万
-
财政年份:2017
-
负责人:PETER T. NELSON
-
依托单位:
Testing a therapeutic strategy for hippocampal sclerosis of aging, a key AD mimic
-
批准号:9055456
-
项目类别:
-
资助金额:$22.58万
-
财政年份:2016
-
负责人:PETER T. NELSON
-
依托单位:
Sexually dimorphic miR-497 regulates alpha-synuclein and alpha-synucleinopathy
-
批准号:8638195
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2013
-
负责人:PETER T. NELSON
-
依托单位:
CELLULAR CHANGES ALTERING SYNAPTIC CONNECTIVITY IN PRECLINICAL AD
-
批准号:9282762
-
项目类别:
-
资助金额:$30.85万
-
财政年份:2013
-
负责人:PETER T. NELSON
-
依托单位:
CELLULAR CHANGES ALTERING SYNAPTIC CONNECTIVITY IN PRECLINICAL AD
-
批准号:9084441
-
项目类别:
-
资助金额:$30.85万
-
财政年份:2013
-
负责人:PETER T. NELSON
-
依托单位:
Sexually dimorphic miR-497 regulates alpha-synuclein and alpha-synucleinopathy
-
批准号:8739560
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2013
-
负责人:PETER T. NELSON
-
依托单位:
Aperio ScanScope XT Digital Slide Scanner System
-
批准号:8051964
-
项目类别:
-
资助金额:$28.37万
-
财政年份:2011
-
负责人:PETER T. NELSON
-
依托单位:
Novel assay identifies all microRNA targets in Alzheimer and normal aged brains
-
批准号:8081746
-
项目类别:
-
资助金额:$15.17万
-
财政年份:2010
-
负责人:PETER T. NELSON
-
依托单位:
Novel assay identifies all microRNA targets in Alzheimer and normal aged brains
-
批准号:7989190
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2010
-
负责人:PETER T. NELSON
-
依托单位:
A specific microRNA (Mir-107) is a potential therapeutic target in Alzheimer's di
-
批准号:8038268
-
项目类别:
-
资助金额:$31.41万
-
财政年份:2008
-
负责人:PETER T. NELSON
-
依托单位:
A specific microRNA (Mir-107) is a potential therapeutic target in Alzheimer's di
-
批准号:7583041
-
项目类别:
-
资助金额:$32.05万
-
财政年份:2008
-
负责人:PETER T. NELSON
-
依托单位:
GENOMIC AND PROTEOMIC DETERMINANTS OF LOWER EXTREMITY REVASCULARIZATION FAILURE
-
批准号:7950750
-
项目类别:
-
资助金额:$1.3万
-
财政年份:2008
-
负责人:PETER T. NELSON
-
依托单位:
A specific microRNA (Mir-107) is a potential therapeutic target in Alzheimer's di
-
批准号:7692308
-
项目类别:
-
资助金额:$32.05万
-
财政年份:2008
-
负责人:PETER T. NELSON
-
依托单位:
Alpha-synuclein mRNA is a putative microRNA target
-
批准号:6849160
-
项目类别:
-
资助金额:$10.98万
-
财政年份:2005
-
负责人:PETER T. NELSON
-
依托单位:
Alpha-synuclein mRNA is a putative microRNA target
-
批准号:6999321
-
项目类别:
-
资助金额:$6.24万
-
财政年份:2005
-
负责人:PETER T. NELSON
-
依托单位:
海外基金